ライフサイエンスコーパス: nonopioid

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 roup (5 vs 11 doses for opioids; 5 vs 10 for nonopioids).

2 The nonopioid actions of spinal dynorphin may promote aspect

3 ain, careful monitoring and consideration of nonopioid alternative treatments is warranted.

4 inophen (paracetamol) may represent a viable nonopioid alternative.

5 calculated the frequency of both opioid and nonopioid analgesia administration using complex survey

6 outstanding questions concerning the use of nonopioid analgesia for stronger cancer pain.

7 tant mice also display significantly greater nonopioid analgesia in response to cold water swim stres

8 Here, we review the evidence for the use of nonopioid analgesic agents in patients with cancer and d

9 Commonly used opioid and nonopioid analgesic drugs produce adverse effects and ar

10 pain, are being replaced by a combination of nonopioid analgesic drugs with diverse modes of action a

11 Testing of an alternative nonopioid analgesic gene, IL-10, alone or in combination

12 This was accomplished by optimizing nonopioid analgesic medications using a stepped care alg

13 a triaminopyridine derivative that acts as a nonopioid analgesic.

14 ions (24.5%), followed by diuretics (22.1%), nonopioid analgesics (15.4%), hypoglycemics (10.9%), and

15 The average +/- SD daily oral intake of nonopioid analgesics (2.6+/-1.4 pills per day) was decre

16 Systemic nonopioid analgesics and adjuvant analgesics may be pres

17 Multimodal analgesia including nonopioid analgesics and ambulatory continuous periphera

18 treatment of sickle pain entails the use of nonopioid analgesics, opioid analgesics, and adjuvants s

19 scussed include nonpharmacologic techniques, nonopioid analgesics, opioids, adjuvant medications, rad

20 ombining regional techniques with opioid and nonopioid analgesics.

21 t on the commissural/associational system, a nonopioid-containing pathway.

22 ficacy of opioids compared with placebo or a nonopioid control did not show reduced pain with opioids

23 ifferences in the neurochemical mediation of nonopioid (i.e., naloxone-insensitive) stress-induced an

24 suggesting that liability likely extends to nonopioid illicit drug dependence.

25 sms involved in the binding of opioid versus nonopioid ligands.

26 (nAChRs) have been proposed as an important nonopioid mechanism based on studies demonstrating preve

27 (ER), an approved analgesic with opioid and nonopioid mechanisms of action and low abuse potential,

28 Where possible, nonopioid medications and regional anesthetic blockade a

29 FACES scores and decreased use of opioid and nonopioid medications compared with LAI.

30 Fewer doses of opioid and nonopioid medications were given to the BRSB group compa

31 ngle-day buprenorphine dosing and adjunctive nonopioid medications, for initiating adults with opioid

32 Sigma receptors (sigmaRs) are nonopioid, nonphencyclidine binding sites with robust ne

33 Sigma receptors (sigmaRs) are nonopioid, nonphencyclidine binding sites with robust ne

34 support the existence of parallel opioid and nonopioid pain modulatory systems and highlight the abil

35 We observed disparities in nonopioid psychotropic use between black and white women

36 ive medications (opioid pain medications and nonopioid psychotropics, including antidepressants/anxio

37 toxicity with similar efficacy, indicating a nonopioid receptor-mediated effect.

38 t of stress-induced analgesia (SIA), whereas nonopioid SIA was not changed.

39 gether, these results define ASIC1a as a new nonopioid target for dynorphin action and suggest that d

40 Of primary importance, nonopioid therapy is preferred for treatment of chronic

41 opioid therapy versus placebo, no opioid, or nonopioid therapy; different opioid dosing strategies; o

42 e pain along with utilization of opioids and nonopioids thus formulating a multimodal approach to pai

43 Nonopioid treatments for pain after therapeutic procedur

44 lockade of TLR4/MD2 by administration of the nonopioid, unnatural isomer of naloxone, (+)-naloxone (r

45 Nonopioids were recommended for mild pain, with the addi

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。